Axsome Therapeutics (AXSM) Accumulated Expenses (2015 - 2026)

Axsome Therapeutics has disclosed Accumulated Expenses across 12 years of filings, most recently posting $43000.0 for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $43000.0, down 99.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $43000.0 (down 99.96% YoY), and the FY2025 annual result was $150.2 million, up 941.14% from the prior year.
• Accumulated Expenses came in at $43000.0 for Q1 2026 at Axsome Therapeutics, down from $150.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $150.2 million in Q4 2025 to a low of $43000.0 in Q1 2026.
• The 5-year median for Accumulated Expenses is $4.5 million (2024), against an average of $22.5 million.
• Across the five-year window, Accumulated Expenses surged 5672.63% in 2025 and tumbled 99.96% in 2026, its largest moves.
• Axsome Therapeutics' Accumulated Expenses stood at $875000.0 in 2022, then soared by 643.2% to $6.5 million in 2023, then jumped by 121.91% to $14.4 million in 2024, then jumped by 941.14% to $150.2 million in 2025, then sank by 99.97% to $43000.0 in 2026.
• The last three Accumulated Expenses figures came in at $43000.0 (Q1 2026), $150.2 million (Q4 2025), and $7.0 million (Q3 2025), per Business Quant data.